Teprotumumab-related Cutaneous Hypersensitivity Reactions

Liane O Dallalzadeh; Michelle Ting; Nicole Topilow; Shira L Robbins; Catherine Y Liu; Cat N Burkat; Bobby S Korn; Don O Kikkawa

doi:10.1097/IOP.0000000000002482

Teprotumumab-related Cutaneous Hypersensitivity Reactions

Ophthalmic Plast Reconstr Surg. 2023 Nov-Dec;39(6):e208-e210. doi: 10.1097/IOP.0000000000002482. Epub 2023 Sep 1.

Authors

Liane O Dallalzadeh¹, Michelle Ting¹, Nicole Topilow¹, Shira L Robbins², Catherine Y Liu¹, Cat N Burkat³, Bobby S Korn^{1

4}, Don O Kikkawa^{1

4}

Affiliations

¹ Division of Oculofacial Plastic and Reconstructive Surgery, Viterbi Family Department of Ophthalmology, Shiley Eye Institute, UC San Diego, La Jolla, CA, U.S.A.
² Division of Pediatric Ophthalmology and Adult Strabismus, Viterbi Family Department of Ophthalmology, University of California San Diego, La Jolla, CA, U.S.A.
³ Division of Ophthalmic Facial Plastic Surgery, Department of Ophthalmology and Visual Sciences, University of Wisconsin Madison, Madison, WI, U.S.A.
⁴ Division of Plastic and Reconstructive Surgery, Department of Surgery, UC San Diego, La Jolla, CA, U.S.A.

PMID: 37656913
DOI: 10.1097/IOP.0000000000002482

Abstract

The authors report 4 cases of cutaneous hypersensitivity reactions developing in the course of teprotumumab treatment for thyroid eye disease. The onset of the cutaneous hypersensitivity reaction was also observed during the treatment course in all cases, between the second and fifth infusions. Teprotumumab-related cutaneous reactions suggest a possible immunogenic component of the monoclonal antibody and highlight the importance of close monitoring during treatment.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized* / adverse effects
Graves Ophthalmopathy*
Humans

Substances

teprotumumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal